Companies in Dermatology
There are 1,728 companies in Dermatology which include LEO Pharma, Revance Therapeutics, Incyte, Evommune, Castle Biosciences. 607 companies in Dermatology are funded, with 350 having secured Series A funding. Till date, the sector has seen the creation of 1 Unicorn. United States has the most number of companies in Dermatology (563), followed by United Kingdom
(130), and then South Korea (109).
2026 has seen the creation of 9 Dermatology companies. On average, the last 10 years have seen 41 new companies launched every year. Most number of Dermatology startups have been founded by alumni from Massachusetts Institute of Technology, Harvard University and Stanford University.
Here is a List of top companies in Dermatology
1. LEO Pharma
Developer of drugs for treating dermatology diseases. It offers variety of medicines such as topical creams and ointments, oral tablets, and injectable biologics for the treatment of psoriasis, eczema, and rare diseases. The pipeline products include Tralokinumab for atopic dermatitis and Delgocitinib a topical pan-JAK inhibitor for chronic hand eczema.
Key facts about LEO Pharma
- Founded Year: 1908
- Location: Copenhagen (Denmark)
- Stage: Late Stage
- Total Funding till date: $560M
- Investors: Nordic Capital
- Latest Funding Round: PE, Mar 31, 2022, $*****
- Tracxn Score: 71/100 What is this?
- Competitors Rank: 8 of 3,205 Competitors
Developer of neurotoxin aesthetic and therapeutic products for skin treatments. It focused on developing innovative products in the aesthetic medicine and personal wellness categories. It has developed a platform technology that enables the delivery of large macromolecules and other potent molecules across the skin. Its aesthetics pipeline includes RT001 for lateral canthal lines and RT002 for glabellar lines. It has the same products as therapies for Hyperhidrosis and Cervical Dystonia.
Key facts about Revance Therapeutics
- Founded Year: 2002
- Location: Newark (United States)
- Stage: Acquired
- Total Funding till date: $155M
- Investors: EW Healthcare Partners, Delphi Ventures and 17 Others
- Latest Funding Round: Series E, Oct 22, 2013, $*****
- Tracxn Score: 70/100 What is this?
- Competitors Rank: 1 of 255 Competitors
3. Incyte
Developer of small molecules for the treatment of different cancer and skin diseases. The company provides Jakafi to treat polycythemia vera (PV) and myelofibrosis (MF). Its product pipeline includes Pemazyre for Cholangiocarcinoma3 Monjuv for lymphoma, Iclusig for chronic myeloid leukemia, ruxolitinib for chronic GVHD, and others.
Key facts about Incyte
- Founded Year: 1991
- Location: Wilmington (United States)
- Stage: Public
- Investors: BB Biotech, Tekla Capital Management and 5 Others
- Latest Funding Round: Post IPO, Nov 14, 2013, $*****
- Tracxn Score: 66/100 What is this?
- Competitors Rank: 49 of 4,204 Competitors
4. Evommune
Developer of therapeutic options for chronic inflammatory disorders. The pipeline drug candidates include v for rosacea, and atopic dermatitis, RORγt for psoriasis, MRGPRX2 for pruritus, and PKCϴ for atopic dermatitis. The company uses a tissue-based screening platform that helps in the drug development of inflammatory diseases.
Key facts about Evommune
- Founded Year: 2020
- Location: Sacramento (United States)
- Stage: Public
- Total Funding till date: $276M
- Investors: Pivotal bioVenture Partners, RA Capital Management and 18 Others
- Latest Funding Round: Post IPO, Feb 12, 2026, $*****
- Tracxn Score: 66/100 What is this?
- Competitors Rank: 47 of 3,542 Competitors
Provider of diagnostic devices for treating cancer. The company's product includes prognostic tests used for uveal melanoma, esophageal cancer, mesothelioma, cutaneous melanoma, and glioblastoma multiforme. The company has also developed DecisionDx DiffDx-Melanoma to diagnose Melanocytic Lesions and others.
Key facts about Castle Biosciences
- Founded Year: 2008
- Location: Friendswood (United States)
- Stage: Public
- Total Funding till date: $62M
- Investors: Industry Ventures, Health Quest Capital and 10 Others
- Latest Funding Round: Post IPO, Jul 29, 2019, $*****
- Tracxn Score: 66/100 What is this?
- Competitors Rank: 1 of 34 Competitors
